Novo Nordisk Upgrades Sales Forecast on Wegovy Demand
Wall Street Journal
Novo Nordisk raised its full-year sales guidance after revenue from its blockbuster Wegovy obesity treatment surged in the second quarter.
Understanding current events through the lenses of the past and future.
Wall Street Journal
Novo Nordisk raised its full-year sales guidance after revenue from its blockbuster Wegovy obesity treatment surged in the second quarter.